Strategies to overcome immune ignorance and tolerance

Seminars in Cancer Biology

Volumn 12, Issue 1, 2002, Pages 63-71

  Perales, Miguel Angel ^a   Blachere, Nathalie E ^a   Engelhorn, Manuel E ^a   Ferrone, Cristina R ^a   Gold, Jason S ^a   Gregor, Polly D ^a   Noffz, Gabriele ^a   Wolchok, Jedd D ^a   Houghton, Alan N ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Cancer; Differentiation antigen; Melanoma; Tolerance; Tumor immunity

Indexed keywords

EPITOPE; GENE PRODUCT; TUMOR ANTIGEN; VIRUS ANTIGEN;

ARTICLE; CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; MELANOMA; MOLECULAR STABILITY; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR IMMUNITY;

EID: 0036153249     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0397     Document Type: Article

References (41)

1. Structure of the gene of tum-transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells
2. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma
3. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription
4. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
5. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
6. Some aspects of normal and abnormal cell surface genetics
7. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets
8. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
9. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product
10. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
11. Identification of TRP-2 as a human TA recognized by cytotoxic T lymphocytes
12. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules
13. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
14. Cross-presentation: A general mechanism for CTL immunity and tolerance
15. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy
16. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (Ad-B7) expression vector
17. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
18. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
19. Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity
20. Heteroclitic immunization induces tumor immunity
21. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex
22. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
23. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
24. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
25. Tumor immunity and autoimmunity induced by immunization with homologous DNA
26. Coupling and uncoupling of tumor immunity and autoimmunity
27. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity
28. Fc receptors are required in passive and active immunity to melanoma
29. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
30. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein
31. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
32. Genetic vaccination with “self” tyrosinase-related protein 2 causes melanoma eradication but not vitiligo
33. Route of immunization and the therapeutic impact of recombinant anticancer vaccines
34. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma
35. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
36. An autologous oral DNA vaccine protects against murine melanoma
37. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor
38. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
39. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells
40. Immunization of melanoma patients with both tyrosinase (370d) and gp100 (210m) peptides: Comparison of adjuvants and peptide immunogenicity
41. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects